Skip to main navigation
Skip to content
Customer Service: 866-788-9007
PHYSICIAN LOGIN   |   CRF LOGIN   
ORDER TEST
Castle Biosciences, Inc.
  • Company
    • About Us
    • History
    • Executive Management
    • Board of Directors
    • Licenses
    • Careers
    • Contact Us
  • Products
    • Cutaneous Melanoma
    • DecisionDx-Melanoma
    • DecisionDx-CMSeq
    • Cutaneous SCC
    • DecisionDx-SCC
    • Uveal Melanoma
    • DecisionDx-UM
    • DecisionDx-UMSeq
    • DecisionDx-PRAME
  • Research & Development
    • Our Approach
    • Tests in Development
    • Suspicious Pigmented Lesions
  • Investors
    • Overview
    • Why Invest
    • News & Events
      • Press Releases
      • Events & Presentations
    • Stock Information
      • Stock Quote & Chart
      • Historic Price Lookup
      • Investment Calculator
      • Annual Reports
    • Financials & Filings
      • SEC Filings
      • Quarterly Results
    • Analyst Coverage
    • Corporate Governance
      • Documents & Charters
      • Board of Directors
      • Management
      • Committee Composition
    • Investor Resources
      • Annual Meeting
      • Investor FAQs
      • Investor Contact
      • Email Alerts
  • Scientific Publications
    • DecisionDx-Melanoma
    • DecisionDx-SCC
    • DecisionDx-UM
  • Resources
    • Healthcare Professionals
    • Login/Register
    • Order a Test
    • Reimbursement
    • Patients
    • Overview of our Tests
    • Frequently Asked Questions
    • Insurance Coverage

Press Releases

Press Releases

February 22, 2021
Castle Biosciences to Release Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call on Monday, March 8, 2021
February 8, 2021
Castle Biosciences to Present at Upcoming Investor Conferences
February 4, 2021
Castle Biosciences Presents New Data on the Validity and Accuracy of DecisionDx-Melanoma in Patients With T1 Cutaneous Melanoma Tumors at the 19th Annual South Beach Symposium
January 20, 2021
Castle Biosciences to Present Data on DecisionDx®-Melanoma, DecisionDx® DiffDx™-Melanoma at 18th Annual Winter Clinical Dermatology Conference
January 13, 2021
Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2020 Results
January 4, 2021
Castle Biosciences to Present at the 23rd Annual Needham Virtual Growth Conference

Site - Investor Tools

Print Page
Print Page
RSS Feeds
RSS Feeds
Email Alerts
Email Alerts
Investor Contact
Investor Contact
Search
Search
 

Connect with Us

Company

  • About Us
  • History
  • Leadership
    • Executive Management
    • Board of Directors
  • Licenses
  • Careers
  • Contact Us

Products

  • Cutaneous Melanoma
    • DecisionDx-Melanoma
    • DecisionDx-CMSeq
  • Uveal Melanoma
    • DecisionDx-UM
    • DecisionDx-UMSeq
    • DecisionDx-PRAME

Research & Development

  • Our Approach
  • Tests in Development
  • Cutaneous Squamous Cell Carcinoma
  • Suspicious Pigmented Lesions

Latest News & Publications

  • Press Releases
  • Scientific Publications
  • Email Alerts

Resources

  • Healthcare Professionals
    • Login/Register
    • Order A Test
    • Reimbursement
  • Patients
    • Overview of our Tests
    • Frequently Asked Questions
    • Insurance Coverage
Copyright © 2021 Castle Biosciences, Inc. | All Rights Reserved
  • Privacy Policy
  • Terms of Use
  • Contact Us
7ads6x98y